相似文献
1
Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India.ChAdOx1 nCoV-19疫苗在印度德尔塔（B.1.617.2）变种激增期间的有效性。
Lancet Infect Dis. 2022 Apr;22(4):446-447. doi: 10.1016/S1473-3099(22)00132-3.
2
Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India - Authors' reply.ChAdOx1新冠疫苗在印度德尔塔（B.1.617.2）变异株激增期间的有效性——作者回复
Lancet Infect Dis. 2022 Apr;22(4):447. doi: 10.1016/S1473-3099(22)00120-7.
3
Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study.比较德尔塔变异株主导大流行期间各种 COVID-19 疫苗方案的真实世界效果：一项病例对照研究。
Emerg Microbes Infect. 2022 Dec;11(1):585-592. doi: 10.1080/22221751.2022.2037398.
4
Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.BNT162b2（辉瑞-生物科技）和 ChAdOx1 nCoV-19（牛津-阿斯利康）疫苗对降低感染 SARS-CoV-2 的 Delta 变体（B.1.617.2）的敏感性的有效性。
BMC Infect Dis. 2022 Mar 20;22(1):270. doi: 10.1186/s12879-022-07239-z.
5
Development of severe pemphigus vulgaris following ChAdOx1 nCoV-19 vaccination and review of literature.接种 ChAdOx1 nCoV-19 疫苗后出现严重寻常型天疱疮：病例报告及文献复习
J Cosmet Dermatol. 2022 Jun;21(6):2311-2314. doi: 10.1111/jocd.14945. Epub 2022 Apr 9.
6
Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports.腺病毒载体 ChAdOx1 nCoV-19 疫苗接种后引发浅静脉血栓形成：两例病例报告
J Med Case Rep. 2022 May 7;16(1):182. doi: 10.1186/s13256-022-03407-6.
7
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.异源 ChAdOx1 nCoV-19 和 BNT162b2 疫苗加强接种可引发针对流行的 SARS-CoV-2 变体的强大中和抗体反应和 T 细胞反应性。
EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.
8
Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis.12 剂小瓶 ChAdOx1 nCoV-19 疫苗对 SARS-CoV-2 的免疫原性：一项中期分析。
Vaccine. 2022 Jan 28;40(4):587-593. doi: 10.1016/j.vaccine.2021.12.023. Epub 2021 Dec 22.
9
Longitudinally extensive transverse myelitis following ChAdOx1 nCoV-19 vaccine.腺病毒载体新冠疫苗接种后发生的纵向广泛横贯性脊髓炎。
J Postgrad Med. 2022 Jul-Sep;68(3):179-181. doi: 10.4103/jpgm.jpgm_1047_21.
10
Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine.假说：抗载体免疫和 SARS-CoV-2 变体对 ChAdOx1 nCoV-19 疫苗效力的可能影响。
Br J Pharmacol. 2022 Jan;179(2):218-226. doi: 10.1111/bph.15620. Epub 2021 Jul 31.
引用本文的文献
1
Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice.扩展的严重急性呼吸综合征冠状病毒2受体结合域加强疫苗接种可诱导小鼠产生体液和细胞免疫耐受。
iScience. 2022 Dec 22;25(12):105479. doi: 10.1016/j.isci.2022.105479. Epub 2022 Nov 2.
本文引用的文献
1
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.在印度 delta（B.1.617.2）变异株流行期间，ChAdOx1 nCoV-19 疫苗对 SARS-CoV-2 感染的有效性：一项基于病例对照研究的疫苗效力评估和接种后免疫反应的机制研究。
Lancet Infect Dis. 2022 Apr;22(4):473-482. doi: 10.1016/S1473-3099(21)00680-0. Epub 2021 Nov 25.
2
Of Cross-immunity, Herd Immunity and Country-specific Plans: Experiences from COVID-19 in India.关于交叉免疫、群体免疫和国家特定计划：印度新冠肺炎疫情的经验
Aging Dis. 2020 Dec 1;11(6):1339-1344. doi: 10.14336/AD.2020.1104. eCollection 2020 Dec.
3
Pre-existing immunity to SARS-CoV-2: the knowns and unknowns.SARS-CoV-2 预先存在的免疫力：已知和未知。
Nat Rev Immunol. 2020 Aug;20(8):457-458. doi: 10.1038/s41577-020-0389-z.
4
The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.应用病例对照研究评估疫苗有效性：方法学系统综述。
Epidemiology. 2020 Jan;31(1):43-64. doi: 10.1097/EDE.0000000000001116.
Zotero 插件